Aventis’ chances of sidestepping the hostile takeover bid from Sanofi-Synthelabo are looking increasingly less likely as the ‘alternative scenarios’ it …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

